Managing severe dyskinesia in Parkinson’s Disease using 24-hour Levodopa/Carbidopa Intestinal Gel Infusion
Objective: We report the effective treatment of troublesome dyskinesias in Parkinson’s disease (PD), unresponsive to 16-hour daytime infusions, using 24-hour Levodopa/Carbidopa Intestinal Gel (LCIG). Background:…Differential Item Functioning in the Unified Dyskinesia Rating Scale (UDysRS)
Objective: Test if differential item functioning (DIF) due to gender, age, race/ethnicity or education level is present in UDysRS items. Background: Testing a rating…An Unusual Cause of Rhabdomyolysis in Parkinson’s disease
Objective: To describe an unusual cause of rhabdomyolysis in patient with advanced Parkinson’s disease (PD) treated with levodopa. Background: Rhabdomyolysis is a serious and life-threatening…Fibroblasts Implanted in Internal Pallidum of Parkinsonian Macaques Exert L-Dopa-Sparing Activity
Objective: To assess the effects of autologous implantation of fibroblasts in the internal globus pallidus of dyskinetic MPTP-lesioned monkeys upon motor behaviour and L-DOPA response.…Effect of levodopa-carbidopa intestinal gel on dyskinesia: Design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients
Objective: To examine the effect of levodopa-carbidopa intestinal gel (LCIG, designated carbidopa-levodopa enteral suspension in the US) treatment relative to that of optimized medical treatment…Regulation of aberrant striatal oscillations by glutamate receptor blockade in parkinsonian non-human primates
Objective: To study the abnormal striatal oscillations and regulation of striatal oscillatory activities by micro-infusion of glutamate receptor antagonist in the non-human primate model of…Inhaling xenon ameliorates L-DOPA-induced dyskinesia in Parkinson disease through normalizing maladaptive corticostriatal plasticity
Objective: To investigate the mechanism(s) of action of xenon inhalation for the treatment of L-DOPA-induced dyskinesia. Background: L-dopa-induced dyskinesia (LID) is one of the most…Ambulatory movement measurement in evaluating deep brain stimulation effect in patients with advanced Parkinson’s disease
Objective: To assess the use of the Parkinson's Kinetigraph™ (PKG™) in evaluating the effect of deep brain stimulation (DBS) in patients with advanced Parkinson's disease (PD). Background: Assessment of the effect of DBS on bradykinesia…Motor effects induced by D1- or D2-like receptor agonists in experimental parkinsonism.
Objective: We set out to compare movement patterns induced by systemic administration of l-dopa versus D1- or D2-class DA receptor agonists in mice with unilateral…Intracerebroventricular administration of dopamine: A new therapeutic concept for Parkinson’s disease?
Objective: In this study, we aim to demonstrate that continuous i.c.v. infusion of dopamine close to the striatum is a feasible and highly efficient treatment…
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 49
- Next Page »